---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-032161"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2024-02-12T23:59:59+00:00"
generated_at: "2026-06-06T04:31:59.961697+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kyverna Therapeutics completes IPO of 16.7M shares at $22.00, gross proceeds $366.9M

## Summary
- Gross proceeds $366.9M from IPO including full exercise of underwriter option to purchase 2.175M additional shares.
- Shares listed on Nasdaq Global Select Market under ticker KYTX.
- Amended charter and bylaws effective upon closing include classified board, exclusive forum provisions, and no cumulative voting.
- Authorized capital: 490M shares of common stock and 10M shares of undesignated preferred stock.

## SEC filing metadata
- accession: 0001193125-24-032161
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2024-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312524032161/0001193125-24-032161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312524032161/d765670d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-032161
- JSON: https://secwatch.observer/filing/0001193125-24-032161.json
- Plain text: https://secwatch.observer/filing/0001193125-24-032161.txt

## Key facts
- Governance Changes
  Kyverna Therapeutics, Inc.: Amended and restated certificate of incorporation and bylaws effective upon closing of IPO, including provisions on capital stock, board classification, exclusive forum, and stockholder action by written consent prohibition (effective 2024-02-12).
  - Change: bylaw amendment
  - Effective: 2024-02-12
  source text: On February 12, 2024, Kyverna Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware, and the Certificate of Incorporation and its amended and restated bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering of shares of the Company’s common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1994702/000119312524032161/0001193125-24-032161-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.